Get the Stockscreener App
2.605
1.76%
0.045
Lakeshore Biopharma Co Ltd stock is traded at $2.605, with a volume of 11,114.
It is up +1.76% in the last 24 hours and down -25.57% over the past month.
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
See More
Previous Close:
$2.56
Open:
$2.57
24h Volume:
11,114
Relative Volume:
0.32
Market Cap:
$50.37M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.58%
1M Performance:
-25.57%
6M Performance:
-35.36%
1Y Performance:
+0.00%
1-Day Range:
$2.51
$2.90
1-Week Range:
$2.31
$2.90
52-Week Range:
$1.88
$9.988
Lakeshore Biopharma Co Ltd Stock (LSB) Company Profile
Name
Lakeshore Biopharma Co Ltd
Sector
Industry
Phone
-
Address
-
Compare LSB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LSB
Lakeshore Biopharma Co Ltd
|
2.51 | 50.37M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.20 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.07 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.73 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.43 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.16 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lakeshore Biopharma Co Ltd Stock (LSB) Latest News
Revenues Working Against LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Share Price Following 27% Dive - Simply Wall St
LakeShore Biopharma : Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full Year Guidance Form 6 K - Marketscreener.com
LakeShore Biopharma Posts First Profit Since 2013, Revenue Soars 36% in Strong H1 Earnings - StockTitan
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance - Finansavisen
LakeShore Biopharma provides update on ongoing investigation involving Yi Zhang - TipRanks
LakeShore Biopharma Pursues Criminal Investigation Against Ex-Chairman for Major Corporate Fraud - StockTitan
LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China - GlobeNewswire
LakeShore Biopharma Faces Challenges Amid Criminal Probe into Former Chairman - TipRanks
Omeros Corp (OMER) Stock Surges Amidst Biotech Sector Activity - GuruFocus.com
LakeShore Biopharma : Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan Form 6 K - Marketscreener.com
LakeShore Biopharma Granted Phase III Clinical Trial Approval to - GuruFocus.com
LakeShore Biopharma Initiates Biologics License Application - GlobeNewswire
LakeShore's Rapid Rabies Vaccine Breakthrough: FDA-Backed Solution Targets Pakistan Crisis | LSB Stock News - StockTitan
Investors Don't See Light At End Of LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Tunnel And Push Stock Down 66% - Simply Wall St
LakeShore Biopharma regains Nasdaq compliance By Investing.com - Investing.com Canada
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - StreetInsider.com
LakeShore Biopharma regains Nasdaq compliance - Investing.com India
LakeShore Biopharma Advances with Rabies Vaccine Trial - Yahoo Finance
LakeShore Biopharma to test simplified rabies vaccine regimen By Investing.com - Investing.com Australia
LakeShore Biopharma's YSJA Rabies Vaccine Heads To Phase III Trial - Contract Pharma
LakeShore Biopharma to test simplified rabies vaccine regimen - Investing.com
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine - StockTitan
LakeShore Biopharma’s YSJA Rabies Vaccine Heads to Phase III Trial - Contract Pharma
YS Biopharma (YSB) Stock Price, News & Analysis - MarketBeat
LakeShore Biopharma projects steady growth for FY2025 By Investing.com - Investing.com Australia
LakeShore Biopharma projects steady growth for FY2025 - Investing.com
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance - The Manila Times
LakeShore Biopharma Co., Ltd Provides Financial Guidance for the Half Year of Fiscal Year of 2025 and Full Year of Fiscal Year 2025 Ending on March 31, 2025 - Marketscreener.com
LSB’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Metric Deep Dive: Understanding LakeShore Biopharma Co Ltd. (LSB) Through its Ratios - The Dwinnex
LakeShore Biopharma Updates Corporate Framework - TipRanks
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation - Kilgore News Herald
Life & Banc Split (TSE:LBS) Sets New 52-Week High at $8.46 - MarketBeat
Multibagger Stock under Rs 20: After stock split, Ok Play allots equities upon warrants conversion - ET Now
Roadwork returns on DLSD: What to know - WBBM
Carvela steps into Lakeside Village - Doncaster Free Press
LakeShore Biopharma Calls for Shareholder Vote on Stock Compliance - TipRanks
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024 - The Manila Times
LakeShore changes CEO with new executive appointments - The Pharma Letter
LakeShore Biopharma names Xu Wang as new CEO - Investing.com India
LakeShore Biopharma names Xu Wang as new CEO By Investing.com - Investing.com Canada
LakeShore Biopharma Announces Leadership Transitions - Kilgore News Herald
Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Short Interest Update - Defense World
YS Biopharma COVID-19 Vaccine Candidate Against Omicron Variant Meets Primary, Secondary Goals - Marketscreener.com
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 - The Manila Times
Short Interest in Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Rises By 20.1% - Defense World
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition - Longview News-Journal
LakeShore Biopharma Insider Ups Holding By 3,083% During Year - Simply Wall St
LakeShore Biopharma Co., Ltd (NASDAQ:LSB) Looks Inexpensive After Falling 36% But Perhaps Not Attractive Enough - Simply Wall St
LakeShore Biopharma Co., Ltd (NASDAQ:LSB): When Will It Breakeven? - Yahoo Finance
LakeShore Biopharma (NASDAQ:LSB) Stock Quotes, Forecast and News Summary - Benzinga
Lakeshore Biopharma Co Ltd Stock (LSB) Financials Data
There is no financial data for Lakeshore Biopharma Co Ltd (LSB). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):